Mono(Adp‐ribosyl)ation enzymes and nad+ metabolism: A focus on diseases and therapeutic perspectives

Abstract

Mono(ADP‐ribose) transferases and mono(ADP‐ribosyl)ating sirtuins use NAD+ to perform the mono(ADP‐ribosyl)ation, a simple form of post‐translational modification of proteins and, in some cases, of nucleic acids. The availability of NAD+ is a limiting step and an essential requisite for NAD+ consuming enzymes. The synthesis and degradation of NAD+, as well as the transport of its key intermediates among cell compartments, play a vital role in the maintenance of optimal NAD+ levels, which are essential for the regulation of NAD+‐utilizing enzymes. In this review, we provide an overview of the current knowledge of NAD+ metabolism, highlighting the functional liaison with mono(ADP‐ribosyl)ating enzymes, such as the well‐known ARTD10 (also named PARP10), SIRT6, and SIRT7. To this aim, we discuss the link of these enzymes with NAD+ metabolism and chronic diseases, such as cancer, degenerative disorders and aging.